因塞特医疗股价应声上涨5.2%，此前该公司宣布其皮肤疾病治疗药物Opzelura获得了欧盟监管机构的积极意见。这一利好消息提振了市场信心，凸显了该疗法在欧洲市场商业化的关键监管进展。
因塞特医疗股价应声上涨5.2%，此前该公司宣布其皮肤疾病治疗药物Opzelura获得了欧盟监管机构的积极意见。这一利好消息提振了市场信心，凸显了该疗法在欧洲市场商业化的关键监管进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.